Publish fast. Openly. Without restrictions.
An open access publishing platform supporting data deposition and sharing: the perfect publication avenue for researchers working in fast paced fields such as infectious diseases research and epidemiology.Submit your research
F1000Research: Rapid dissemination of research when it’s needed most
F1000Research facilitates the rapid and transparent sharing of research by providing fast, open publication alongside access to any underlying data, software code and resources. All research articles are reviewed post publication, with expert peer review reports freely available.
F1000Research is particularly suited to fast paced areas of research such as infectious diseases research and epidemiology, where immediate access to robust and rigorous science is essential for informing clinical and public health responses in real time.
F1000Research has set up a dedicated section within the Disease Outbreaks Gateway for the publication of COVID-19 related research. We welcome all types of publications related to coronavirus, including but not limited to: clinical trials, clinical case reports, epidemiological modelling, transmission dynamics, collaboratively written policies, protocols, and any other information that needs to be shared rapidly.
Articles published on F1000Research are subject to our Article Processing Charges. For COVID-19 research there is no charge to publish posters, slides and research-related outputs that do not require peer review.
The Disease Outbreaks Gateway on F1000Research
Our median publication times* for COVID-19 articles are:
Benefits of the F1000Research publishing model
See your article published in a matter of days, fully citable and ready for peer review. COVID-19 papers take a median of seven days from submission to publication, and 16 days from publication to peer review.
Wide range of research
We support the publication of research protocols and methods (as Registered Reports as required), data articles, software tool articles and case studies, alongside systematic reviews and research articles.
We can include interactive data tables and figures to support longitudinal time series and quantitative data, providing a quick, easy and cost-effective way to provide updates.
Our versioned publication system means that updates to studies can be made easily and quickly, without the need to publish a new paper. Versions are linked and are individually citable, and older versions will display a clear notification that a new version has been uploaded so that readers are always kept up to date with the latest developments in your work.
Alternative research outputs
We also publish research-related outputs that do not require peer review, such as policy documents, guidelines and technical reports that may, for example, guide health care and disease management practices, for health and allied professionals in such emergencies. We also publish posters and slide decks.
COVID-19 Rapid Review Initiative
COVID-19 on F1000Research
A selection of our latest published research
Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates
Yu Wai Chen, Chin-Pang Bennu Yiu, Kwok-Yin Wong
Chen et al. utilised a 3D model of the SARS-CoV-2 3C-like protease to screen for potential inhibitors. Hepatitis C treatments ledipasvir or velpatasvir were identified as potential inhibitors with minimal associated side-effects, as were their dual component variants that are combined with sofosbuvir that inhibits the viral RNA-dependent RNA polymerase.
Lee et al. aligned the proteome of SARS-CoV-2 to viral immunogenic peptides to identify potential vaccine targets. The authors were able to identify 63 potential peptides with high immunogenicity potential based on HLA allele binding and T Cell receptor recognition potential.
Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China
The author discusses potential therapeutic strategies ranging from repurposing small molecule inhibitors to biologics. A biologic using a soluble version of the ACE2 viral target combined with a immunoglobin Fc domain is proposed as the most effective, which will provide a neutralizing therapy that will also recruit the immune system.
This document presents a variety of strategies for increasing and ensuring higher levels of student engagement in online teaching during the COVID-19 outbreak.